Jazz Pharmaceuticals plc is still feeling the weight of the pandemic on its epilepsy drug Epidiolex (cannabidiol), but it anticipates that COVID-19 vaccinations for young children will give a boost to sales of the cannabis-based drug, which the company sees as having “blockbuster potential.”
Jazz said 9 November that overall revenues for the company saw a significant gain in the third quarter from the...






![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
